Shrank Grade 4 GBM -2cm in 1 month

In March 2024, Mas Masqul Haq was diagnosed with grade 4 astrocytoma, also known as glioblastoma multiforme (GBM)—an aggressive and fast-growing form of brain cancer. The tumor was located in the right hemisphere of his brain, affecting critical regions responsible for cognition and motor function. He underwent brain surgery in Malaysia's hospital, followed by a course of radiation therapy and chemotherapy, including oral chemo pills, as per standard treatment protocols. However, just three months after surgery, an MRI scan performed on 26 June 2024 revealed a disturbing recurrence:

• A prominent tumor mass had returned at the surgical site.

• Small enhancing lesions had begun to appear deeper in the central nervous system, indicating possible early spread.

• The scans also showed extensive surrounding edema, which can worsen symptoms like headaches and neurological deficits.

This pattern of recurrence is unfortunately common. Glioblastoma has a recurrence rate of over 90% after surgery, and even with aggressive treatment, long-term survival is rare. In light of this, new therapies are being added to standard care. In the United States, electric field therapy, such as Tumor Treating Fields (TTF), is now recommended as part of GBM treatment by the National Comprehensive Cancer Network (NCCN) Guidelines (2022). TTF has shown promising results in improving survival and quality of life for patients with GBM.

Due to the relapse and limited treatment options, Mas Masqul began ECCT in September 2024, a non-invasive modality that uses low-intensity electric fields to selectively target and disrupt cancer cell replication. He is determined to Shrank Grade 4 GBM.

By January 2025, just four months into ECCT, his MRI (dated 13 January 2025) showed:

• A noticeable reduction in tumor size.

• Less aggressive contrast enhancement, suggesting decreased tumor activity.

• The small lesion in the central brain region was shrinking.

• Edema had reduced, and the tumor’s borders appeared less defined, likely due to cell death or regression.

This encouraging trend continued. On 3 July 2025, after nine months of consistent ECCT therapy, another MRI scan demonstrated:

• The once large tumor mass had become highly indistinct—almost unidentifiable.

• The small CNS lesions had nearly disappeared.

• Minimal surrounding edema remained, and the overall brain architecture appeared more normalized.

Clinically, Mas Masqul remained in stable condition. Despite the severity of his diagnosis, he was able to walk, eat, and communicate normally, without major neurological deterioration. His quality of life significantly improved compared to his condition prior to ECCT.

📅 Date	🧠 MRI Findings	🔎 Interpretation
26 June 2024	Large tumor recurrence, CNS lesions, significant edema	Active, relapsed disease post-surgery
13 January 2025	Tumor shrinking, reduced enhancement, early lesion disappearing	Early positive response to ECCT
3 July 2025	Tumor barely visible, CNS lesions nearly gone, minimal edema	Strong response, disease under control

Mas Masqul Haq’s journey demonstrates the effect of ECCT in managing recurrent glioblastoma, especially in cases where standard therapies are no longer effective. His remarkable radiological and clinical response underscores the value of integrating innovative electric field-based therapies into the treatment landscape for GBM. While glioblastoma remains one of the most challenging cancers to treat, Mas Masqul’s case is a powerful reminder that with the right approach, even aggressive cancers can be held at bay—restoring not just health, but hope.